世界の医療・医薬品産業レポート

TOP  >  疾患別治験・パイプラインレポート  >  腫瘍  >  癌による食欲不振-悪質液症候群 - パイプラインレビュー 2017年下半期

癌による食欲不振-悪質液症候群 - パイプラインレビュー 2017年下半期
Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2017

レポートタイトル 癌による食欲不振-悪質液症候群 - パイプラインレビュー 2017年下半期
出版社名 Global Markets Direct
発刊日 2017-09-12
体裁 PDF / 93 ページ
シングルユーザ価格 US$ 2,000
レポート分類 疾患別治験・パイプラインレポート
地域 グローバル
領域 腫瘍
疾患名 癌による食欲不振-悪質液症候群
薬剤名 -
企業名 -
備考 ※ ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※ 本レポートは、英文です。PDF(電子媒体)での納品となります。

レポート概要

このレポートは、世界の主要国における上記疾患の治療薬開発についての包括的情報、さまざまな開発ステージでの比較分析、薬剤ターゲット、作用機序(MoA)、投与方法(RoA)、分子タイプ別の薬剤評価、および最新情報、ニュースやプレスリリースなどを提供します。
また、上記疾患における治療薬開発に関わる主要企業概要、開発後期および中止プロジェクトの特集などを提供します。


Global Market Direct社のレポートは、20の治療領域および3000もの適応症をカバーした治験薬を特集しています。
本レポートは、Global Market Direct社独自のデータベース、企業/大学ウェブサイト、SEC書類、企業や大学のウェブサイトからのプレゼンテーションやプレスリリース、および業界特有の第三者情報源、自社分析を基にしたデータや情報を盛り込んでいます。


本レポートは、意思決定能力を高め、競争上の優位性を得るための効果的な戦略を立案するのに役立ちます。
ファーストインクラスやベストインクラス製品を作り出すため、新たなターゲットやMOAを特定することにより、R&Dパイプラインを強化します。


注)本レポートの一部のセクションは、該当疾患におけるデータの可用性や妥当性に基づいて、削除または変更される場合があります。

目次

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cancer Anorexia-Cachexia Syndrome - Overview
Cancer Anorexia-Cachexia Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cancer Anorexia-Cachexia Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cancer Anorexia-Cachexia Syndrome - Companies Involved in Therapeutics Development
Abreos Biosciences Inc
Acacia Pharma Ltd
Aeterna Zentaris Inc
Incyte Corp
Lakewood-Amedex Inc
Novartis AG
Paradigm Biopharmaceuticals Ltd
RaQualia Pharma Inc
Viking Therapeutics Inc
Zeria Pharmaceutical Co Ltd
Cancer Anorexia-Cachexia Syndrome - Drug Profiles
(formoterol fumarate + megestrol acetate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
anamorelin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-380 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVGN-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-1889 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DLN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENERGIF-706 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Foxo1-nRNA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Inhibit Activin A for Osteoporosis and Cancer Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IP-1510 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
macimorelin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-1940 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptide to Inhibit CIDEA for Cancer Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00433412 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ruxolitinib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Cancer Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TCMCB-07 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VK-5211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Z-505 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cancer Anorexia-Cachexia Syndrome - Dormant Projects
Cancer Anorexia-Cachexia Syndrome - Discontinued Products
Cancer Anorexia-Cachexia Syndrome - Product Development Milestones
Featured News & Press Releases
May 18, 2017: Helsinn Announces Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride)
Feb 13, 2017: Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen
Jun 01, 2016: Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis From two Phase III Studies for Anamorelin in Cachectic Patients With Non-small Cell Lung Cancer
Feb 23, 2016: Helsinn Announces Publication of Anamorelin ROMANA 1 and ROMANA 2 Phase III Studies in The Lancet Oncology
Nov 30, 2015: Helsinn Announces European Medicines Agency Acceptance of Marketing Authorization Application for Anamorelin HCL
Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology
Sep 26, 2014: AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference
Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130
Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130
Dec 07, 2011: Helsinn Initiates Extension Study In Late-Stage Anamorelin Clinical Program For Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia
Dec 06, 2011: Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study
Nov 28, 2011: FDA Grants IND To Investigator At Baylor College Of Medicine For Phase IIa Trial With AEZS-130 In Cancer Cachexia
Aug 24, 2011: Helsinn Therapeutics Initiates Phase III Clinical Program To Evaluate Anamorelin In Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia
Apr 26, 2007: Sapphire Therapeutics, Inc. to Present Results From Anamorelin Phase II Cachexia/Anorexia Studies at American Society of Clinical Oncology and Endocrine Society Annual Meetings in June
Dec 15, 2005: Sapphire Therapeutics, Inc.’s Oral Ghrelin Mimetic Shows Potential for Treating Cancer Anorexia/Cachexia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Figures
Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

List of Tables
Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Cancer Anorexia-Cachexia Syndrome - Pipeline by Abreos Biosciences Inc, H2 2017
Cancer Anorexia-Cachexia Syndrome - Pipeline by Acacia Pharma Ltd, H2 2017
Cancer Anorexia-Cachexia Syndrome - Pipeline by Aeterna Zentaris Inc, H2 2017
Cancer Anorexia-Cachexia Syndrome - Pipeline by Incyte Corp, H2 2017
Cancer Anorexia-Cachexia Syndrome - Pipeline by Lakewood-Amedex Inc, H2 2017
Cancer Anorexia-Cachexia Syndrome - Pipeline by Novartis AG, H2 2017
Cancer Anorexia-Cachexia Syndrome - Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017
Cancer Anorexia-Cachexia Syndrome - Pipeline by RaQualia Pharma Inc, H2 2017
Cancer Anorexia-Cachexia Syndrome - Pipeline by Viking Therapeutics Inc, H2 2017
Cancer Anorexia-Cachexia Syndrome - Pipeline by Zeria Pharmaceutical Co Ltd, H2 2017
Cancer Anorexia-Cachexia Syndrome - Dormant Projects, H2 2017
Cancer Anorexia-Cachexia Syndrome - Dormant Projects, H2 2017 (Contd..1), H2 2017
Cancer Anorexia-Cachexia Syndrome - Discontinued Products, H2 2017
Loading....